Macmillan Cancer Support

Macmillan Cancer Support, founded in 1911 and based in London, is a not-for-profit organization dedicated to providing comprehensive support for individuals affected by cancer. Recognizing the profound impact of a cancer diagnosis, Macmillan offers a range of services designed to help people regain control over their lives. These services include financial guidance, employment advice, and emotional support through dedicated listening services. The organization aims to address both practical and emotional challenges faced by cancer patients and their families, ensuring they receive the assistance they need during difficult times.

Felix Litzkow

Head of Impact Investment Principal

5 past transactions

Dxcover

Venture Round in 2025
Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

OXcan

Series A in 2025
OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.

52 North

Venture Round in 2024
52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.

Leo Cancer Care

Series C in 2024
Leo Cancer Care is an innovative company based in Australia that focuses on enhancing the patient experience in cancer radiation therapy. The company has developed a specialized treatment system that emphasizes the clinical benefits of upright patient positioning, which aims to improve patient comfort and control during treatment. By integrating advanced technology with a radiotherapy machine, Leo Cancer Care's system facilitates 3D image capturing and precise control of radiation beams, ensuring that the appropriate amount of energy is delivered to targeted tissues. This approach not only simplifies the radiation therapy process but also aims to reduce the pain and costs associated with traditional chemotherapy and radiation treatments, ultimately connecting patients to centralized cancer care centers for more effective treatment options.

52 North

Seed Round in 2023
52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.